A long‐acting pegylated recombinant human growth hormone (Jintrolong®) in healthy adult subjects: Two single‐dose trials evaluating safety, tolerability and pharmacokinetics.
Summary: What is known and objective: Jintrolong® is a pegylated recombinant human growth hormone (rhGH) (PEG‐rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single‐dose Jintrolo...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 43; no. 5; pp. 640 - 647 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |